v3.25.4
Condensed Consolidated Statements of Cash Flows - USD ($)
9 Months Ended 12 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Dec. 31, 2024
Dec. 31, 2023
CASH FLOWS FROM OPERATING ACTIVITIES        
Net loss $ (19,773,114) $ (544,162)    
Adjustments to reconcile net loss to net cash used in operating activities:        
Amortization of debt discount 2,021,209    
Loss on extinguishment of debt 364,109    
Change in fair value of derivative liabilities (390,744)    
Stock based compensation 14,131,250    
Increase in current assets        
Prepaid expenses (190,065) (132,500)    
Inventory (35,437)    
Increase in current liabilities        
Accounts payable (277,250) (68,093)    
Accrued expenses 265,421    
Other current liabilities (111,026)    
Net cash flows provided by (used in) operating activities (3,995,647) (744,755)    
CASH FLOWS FROM FINANCING ACTIVITIES        
Issuance of common stock 257,645    
Short term loan from shareholders 492,477    
Proceeds from recapitalization 265,827    
Proceeds from issuance of convertible notes 10,250,000    
Repayment of convertible notes (3,032,645)    
Repayment of subscription agreement loan (483,474)    
Transaction costs paid in connection with convertible notes (907,499)    
Proceeds from notes payable - related party 50,000    
Repayment of notes payable - related party (201,924)    
Net cash flows provided by (used in) financing activities 5,940,285 750,122    
NET CHANGE IN CASH 1,944,638 5,367    
CASH, BEGINNING OF THE PERIOD 3,633 11,174 $ 11,174  
CASH, END OF THE PERIOD 1,948,271 16,541 3,633 $ 11,174
Supplemental disclosure of noncash investing and financing activities:        
Accounts payable and other liabilities combined, net 4,868,403    
Loss pursuant to settlement agreement 317,250    
Issuance of shares in reverse acquisition 4,602,576    
Conversion of warrants 574    
Issuance of shares under working capital loans and non redemption agreements 554    
Issuance of commitment fee shares under ELOC agreement 110    
Interest paid 44,388    
Aspire Biopharma Inc [Member]        
CASH FLOWS FROM OPERATING ACTIVITIES        
Net loss     (1,309,872) (359,070)
Adjustments to reconcile net loss to net cash used in operating activities:        
Stock based compensation     356,032 100,000
Depreciation and amortization    
Increase in current assets        
Prepaid expenses     (109,356) (12,500)
Subscription Receivable    
Increase in current assets     (109,356) (12,500)
Increase in current liabilities        
Accounts payable and accrued liabilities     247,846 50,038
Short-term loans from shareholders (net)     906,196 332,668
Increase in current liabilities     1,154,042 382,706
Net cash flows provided by (used in) operating activities     (265,186) 11,136
Cash Flows from Investing Activities:        
Net cash provided by (used in) investing activities    
CASH FLOWS FROM FINANCING ACTIVITIES        
Series A Preferred stock, par value $0.0001     32
Additional paid in capital     257,613
Net cash flows provided by (used in) financing activities     257,645
NET CHANGE IN CASH     (7,541) 11,136
CASH, BEGINNING OF THE PERIOD $ 3,633 $ 11,174 11,174 38
CASH, END OF THE PERIOD     3,633 11,174
Supplemental cashflow information:        
Cash paid for interest    
Cash paid for income taxes     1,013
Note Payable addition from OID     $ 280,549